Samatasvir

Drug Profile

Samatasvir

Alternative Names: IDX-18719; IDX-719; MK-1894

Latest Information Update: 02 Jun 2015

Price : $50

At a glance

  • Originator Idenix Pharmaceuticals
  • Developer Janssen Pharmaceuticals; Merck & Co
  • Class Antivirals; Benzimidazoles; Carbamates; Imidazoles; Pyrrolidines; Thiophenes
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Hepatitis C
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 01 Apr 2015 Merck and Janssen complete the phase II HELIX-1 trial in Hepatitis C (Combination therapy, Treatment-naive) in USA (NCT01852604)
  • 20 Feb 2015 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-naive, Treatment-experienced) in USA (PO) (Merck & Co, pipeline, February 2015)
  • 20 Feb 2015 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in USA (PO) (Merck & Co, pipeline, February 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top